Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.

Also called NCT01413048

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 260 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01413048
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01413048. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Carvedilol 25mg
Intervention (Drug)
AGSCT101 12.5mg
Lead sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd (class: industry)

Record details

Record id
cardio:ct-nct01413048
Content hash
91d468272e992bbff6dc2efea274dea98444bd29535e0554b3bb8b015c81733e